Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn\'s Disease (CD) and previously treated with infliximab
Epistemonikos ID: 567b6a8577390cc6a25de2765a37f3beb5bbe3af
First added on: Aug 06, 2018